The NeurologyLive® dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
March 25th 2024
Here's some of what is coming soon to NeurologyLive® this week.
FAQs in MS: Exploring Provocative Questions From MS Meeting Updates
View More
BURST CME™: Taking ALS Management to the Next Level
View More
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
Improving Care for Patients with Motor Complications of Parkinson Disease: Role of Technology and Data
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Burst CME: Optimizing Therapy in Parkinson’s Disease
View More
Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Individualizing Treatment for Patients with Generalized Myasthenia Gravis
View More
Early Dementia Is Associated With Significant Financial Burden for Patients and Caregivers
June 5th 2020The GERA-US study assessed societal costs associated with MCI and mild dementia, and caring for someone with Alzheimer disease, and was the first such study to show how the early stages of cognitive decline economically impact both patients and their caregivers.
NIH Data Suggest Brain Glucose Metabolism Is Linked to Alzheimer Pathogenesis
May 22nd 2020The data included more than 2000 brains and approximately 400 cerebrospinal fluid samples, and showed that a protein network module linked to glucose metabolism was also elevated in cerebrospinal fluid in early stages of the disease.
Plasma P-Tau181 Biomarker May Be Accessible, Scalable Test for Alzheimer Disease
May 20th 2020Findings from an analysis of a large population of individuals suggest that the blood immunoassay can predict tau and amyloid-ß pathologies, as well as differentiate and identify Alzheimer disease across the clinical spectrum.
Howard Fillit, MD: Aducanumab Findings Lead the Way in Dementia
May 20th 2020The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation discussed the landmark findings from Biogen on its agent aducanumab and the impact the trial might have on the future.
ADDF Diagnostic Accelerator Initiative Invests In Digital Memory Impairment Projects
May 17th 2020The Alzheimer’s Drug Discovery Foundation made 5 new investments through its Diagnostics Accelerator initiative, through which it has $50 million in commitments from leading scientific philanthropists such as Leonard A. Lauder, Bill Gates, Jeff Bezos, and MacKenzie Bezos.
Howard Fillit, MD: Telemedicine and Tech in the Future Care of Alzheimer and Dementia
May 6th 2020The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation detailed what he foresees the future of Alzheimer and dementia care to look like with telemedicine as a more permanent aspect of care.
Howard Fillit, MD: The Positives of Telemedicine Adoption for Geriatric Patients
May 2nd 2020The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation spoke to the way the COVID-19 pandemic has transformed the use of telemedicine for the elderly with conditions like Alzheimer and dementia.
Solanezumab, Gantenerumab Fail to Slow Alzheimer Progression, But DIAN-TU Trial Sheds Positive Light
April 6th 2020Despite solanezumab (Eli Lilly) and gantenerumab (Roche and Genentech) failing to meet the DIAN-TU trial primary end point in inherited Alzheimer disease, the international undertaking provided some positive takeaways for the clinical community.
Compulsive Behaviors May Be More Likely in Parkinson Disease Dementia
April 5th 2020A multicenter, cross-sectional, observational, Spanish nationwide study’s findings suggest that those with Parkinson disease dementia may be predisposed to impulse control disorder symptoms and related behaviors.